Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Revenue: 2016-2025

Historic Revenue for Akebia Therapeutics (AKBA) over the last 9 years, with Sep 2025 value amounting to $58.8 million.

  • Akebia Therapeutics' Revenue rose 57.01% to $58.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.1 million, marking a year-over-year increase of 1626.53%. This contributed to the annual value of $160.2 million for FY2024, which is 1501.80% up from last year.
  • As of Q3 2025, Akebia Therapeutics' Revenue stood at $58.8 million, which was down 5.93% from $62.5 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Revenue ranged from a high of $126.4 million in Q2 2022 and a low of -$128.4 million during Q4 2023.
  • Moreover, its 3-year median value for Revenue was $43.6 million (2024), whereas its average is $31.7 million.
  • Per our database at Business Quant, Akebia Therapeutics' Revenue surged by 225.04% in 2021 and then tumbled by 330.23% in 2023.
  • Akebia Therapeutics' Revenue (Quarterly) stood at $57.7 million in 2021, then declined by 3.29% to $55.8 million in 2022, then plummeted by 330.23% to -$128.4 million in 2023, then skyrocketed by 136.21% to $46.5 million in 2024, then spiked by 57.01% to $58.8 million in 2025.
  • Its Revenue was $58.8 million in Q3 2025, compared to $62.5 million in Q2 2025 and $57.3 million in Q1 2025.